Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT pharmacokinetics in pediatric botulism patients
NCT02051062Phase 4Enrolling by invitation
- Sponsor
- Emergent BioSolutions
- Start
- Oct 2014
- Primary completion
- Jul 2028
- Modality
- Recombinant Proteins and Enzymes, Antibody Fragments
01
Overview
Phase 4, open-label, single-arm trial of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) in botulism, sponsored by Emergent BioSolutions. Primary endpoint: Margin of PK Equivalence for 90% Survival at 32 hours. Started Oct 2014; status: enrolling by invitation.
02
Drugs
Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine)
03
Conditions
botulism
Beyond the preview
Go deeper on NCT02051062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02051062.